Regulators Promote Early Process Understanding As Key To Success In Cell Therapy Manufacturing
Executive Summary
US and Canadian regulators espouse the need for early – and deep – knowledge of cell and gene therapy products as they progress through the pipeline to commercialization. Not doing so compromises product quality, and increases risks to patients.
You may also be interested in...
Cell And Gene Therapies: Where Few Standard Rules Apply
Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.